SK Life Science, Inc.
Clinical trials sponsored by SK Life Science, Inc., explained in plain language.
Now part of
SK Biopharmaceuticals Co., Ltd.
326030
KRX
US subsidiary of SK Biopharmaceuticals, developing CNS drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for kids with focal seizures: cenobamate trial underway Results expected Nov 2026 (estimated)
- New epilepsy drug tested as standalone treatment Results expected May 2027 (estimated)